Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Vaezi, Mohammad  [Clear All Filters]
2024
Kaveh-Ahangaran R, Abdollahi M, Vaezi M, Kasaeian A, Bahlouli Z, Janbabaei G, Mojtahedzadeh A, Mojtahedzadeh M, Djalalinia S, Shahrami B. Oral regimen for high dose methotrexate urine alkalinization: a systematic review and meta-analysis. Daru. 2024.
Keramatikerman M, Varaei S, Vaezi M, Sayadi L. Peer support-based online education, burden of care and quality of life among family caregivers of patients with leukaemia: non-randomised clinical trial. BMJ Support Palliat Care. 2024.
2023
Kazemi-Sefat GEnsieh, Keramatipour M, Vaezi M, Razavi SMohsen, Kavousi K, Talebi A, Rostami S, Yaghmaie M, Chahardouli B, Talebi S, et al. Author Correction: Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model. Sci Rep. 2023;13(1):736.
Aliabadi LSharifi, Karami M, Barkhordar M, Nazari SSaeed Hash, Kavousi A, Ahmadvand M, Vaezi M. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial. Front Immunol. 2023;14:1237916.
Barkhordar M, Chahardouli B, Biglari A, Ahmadvand M, Bahri T, Alaeddini F, Aliabadi LSharifi, Noorani SSaeid, Amiri FBagheri, Biglari M, et al. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study. Front Immunol. 2023;14:1169666.
Heidari S, Panahishokouh M, Babakhani D, Aghabeigi S, Vaezi M, Amini S, Hadjibabaie M, Shahrami B. Vincristine-Induced Seizure from Drug Interactions: A Case Report and Review of Literature. Case Rep Oncol. 2023;16(1):363-371.
2022
Vaezi M, Souri M, Setarehdan SAmin, Hamidieh AAli, Fazlollahi MReza, Pourpak Z, Badalzadeh M, Tajik S, Mahdaviani SAlireza, Alimoghaddam K, et al. A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review. Ann Hematol. 2022.
2021
Tehrani HAzhdari, Darnahal M, Vaezi M, Haghighi S. COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review. Int Immunopharmacol. 2021;93:107397.
2019
Mousavi SAsadollah, Kasaeian A, Pourkasmaee M, Ghavamzadeh A, Alimoghaddam K, Vaezi M, Fumani HKamranzade, Babakhani D, Tavakoli S. Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. PLoS One. 2019;14(1):e0208701.
2016
Vaezi M, Black C, Gibbs DMR, Oreffo ROC, Brady M, Moshrefi-Torbati M, Yang S. Characterization of New PEEK/HA Composites with 3D HA Network Fabricated by Extrusion Freeforming. Molecules. 2016;21(6).
Mohammadi M, Vaezi M, Mirrahimi B, Hadjibabaie M. Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons. Int J Hematol Oncol Stem Cell Res. 2016;10(1):42-50.
Vaezi M, Gharib C, Souri M, Ghavamzadeh A. Late Complications in acute Leukemia patients following HSCT: A single center experience. Int J Hematol Oncol Stem Cell Res. 2016;10(1):1-6.
2015
Vaezi M, Bahar B, Mousavi A, Yaghmai M, Kasaeian A, Souri M, Jahani M, Alimoghaddam K, Ghavamzadeh A. Comparison of 60 and 80 mg/m(2) of daunorubicin in induction therapy of acute myeloid leukaemia. Hematol Oncol. 2015.
2014
Ataei S, Hadjibabaie M, Moslehi A, Taghizadeh-Ghehi M, Ashouri A, Amini E, Gholami K, Hayatshahi A, Vaezi M, Ghavamzadeh A. A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2014.
Jalali A, Alimoghaddam K, Mahmoudi M, Mohammad K, Mousavi SAsadollah, Bahar B, Vaezi M, Zeraati H, Jahani M, Ghavamzadeh A. The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks. Int J Hematol Oncol Stem Cell Res. 2014;8(2):1-8.